8
Clinical research: Department Of Dermatology UHZ, Clinical Trial Unit
Clinical research gains increasing importance and is a major focus at academic centers such as ours. It is essential not only to translate basic research into beneficial treatment regimens, but also to learn from the conducted trials by integrating translational research projects into daily practice. The increasing complexity of contemporary clinical trials requires a well-regulated network, which combines clinical, ethical, legal and economic aspects. A team of clinical trial specialists, including physicians, study nurses and assistants, clinical trial pharmacists, study coordination, finance, quality management and data management team, is necessary to ensure frictionless integration of clinical trials into the treatment strategy for the respective disease. The Clinical Trial Unit within the Department of Dermatology is a major research center for the development of targeted therapies and immunotherapies for skin cancers and immune-mediated skin diseases. Throughout the years, we have collected extensive experience in early and late phases of clinical development (phase I-IV). The Clinical Trial Unit is certified by the Swiss Association for Clinical Cancer Research (SAKK) to perform phase I trials/ first-in-human (FIH) studies since September 12, 2016 and offers a post-graduate study in pharmaceutical medicine. The unit also has its own clinical trial pharmacy with four dedicated trial pharmacists, who have established pharmaceutical management processes that have further elevated the level of quality for our trial patients.
In recent years, the Clinical Trial Unit has worked with many therapeutics for a large number of dermatooncologic and dermatologic indications. Some of the disease entities for which we conducted clinical trials are: – Melanoma (metastatic, neoadjuvant and adjuvant setting) – Non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma, Merkel-cell carcinoma) – Cutaneous T- and B-cell lymphoma – Psoriasis vulgaris – Psoriasis pustulosa – Urticaria – Mastocytosis – Pyoderma gangrenosum – Atopic dermatitis – Hidradenitis suppurativa
Among other molecules, we also worked with the following small molecules, immunotherapies and biologics: – BRAF and MEK inhibitors – Pan-RAF inhibitors including RAF265, LXH254 – Pan-Kinase and tyrosine kinase inhibitors including nilotinib, pazopanib, lapatinib and sorafenib – VEGFR inhibitors, such as lenvatinib – Hedgehog pathway inhibitors – Histone deacetylase inhibitors (HDACi) – RXR retinoids – Immune checkpoint inhibitors (ICI), such as anti CTLA-4, anti-PD1, anti-PDL1 and anti-LAG3 antibodies – Bi-specific protein targeting T cell receptors for IMCgp100 – Combination therapies with ICI and kinase inhibitors, such as vemurafenib, cobimetinib, ribociclib and lenvatinib – Combination of different immunotherapy agents including anti-PD1, anti-LAG3 and IDO1 inhibitor epacadostat – Sting agonists, and anti-M-CSF antibodies, MDM2 inhibitors – Oncolytic therapy with T-VEC, Coxsackievirus A21, Allovectin-7, adenointerferon gamma and canary pox viral vectors – Cancer vaccines – Antimicrobial agents (taurolidine) – Somatostatin-analogons – Antisense-BCL-2 nucleotides – Cytokine fusion proteins – PEG interferon – NAD+ biosynthesis inhibitors – Purine nucleoside phosphorylase inhibitors – TRL agonists, such as resiquimod – TNF-α inhibitors – IL-12/23 inhibitors – IL-17A and IL-17R inhibitors – IL-23 inhibitors – IL-4 R inhibitors – IL-1β antagonists – IL-1Ra soluble receptor – Anti-IgE inhibitors – PDE4 inhibitors – Other molecules
37
